Augmenting the responses to checkpoint inhibitors, which remove the “breaks” from the immune response, is a very popular area of research. The general concept is to turn immunologically cold tumors hot. For example, triple negative breast cancer (TNBC) is considered an immunologically cold tumor – anti-PD(L)1 therapy has shown responses of just 5-10%. Continue reading
Tag Archives: Myeloid-Derived Suppressor Cells
Peripheral white blood cell profiles may predict response to checkpoint blockade
While some patients enjoy excellent and durable responses to treatment with checkpoint inhibits, most do not, and some even hyper-progress. Selecting patients who will benefit most has been challenging. Continue reading
CSF-1 Inhibitor PLX3397 + Keytruda (Anti-PD1) for Multiple Cancers
Colony Stimulating Factor (CSF-1) is an essential growth factor for cells of the monocyte-macrophage lineage, including osteoclasts.
Continue reading
Mystery of Myeloid-Derived Suppressor Cells in Cancer SOLVED
Researchers at St. Jude Children’s hospital have identified the population of white blood cells that tumors use to propagate their growth AND to suppress the immune system. Continue reading